Anaplerotic triheptanoin diet enhances mitochondrial substrate use to remodel the metabolome and improve lifespan, motor function, and sociability in MeCP2-null mice

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Park, Min Jung ^a   Aja, Susan ^a   Li, Qun ^a   Degano, Alicia L ^a,b   Penati, Judith ^a   Zhuo, Justin ^a   Roe, Charles R ^a   Ronnett, Gabriele V ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^c Janssen Research Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; LEPTIN; METHYL CPG BINDING PROTEIN 2; TRIHEPTANOIN; MECP2 PROTEIN, MOUSE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ARTICLE; CITRIC ACID CYCLE; DIET THERAPY; FATTY ACID METABOLISM; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEMIZYGOSITY; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; KNOCKOUT MOUSE; LIFESPAN; LONGEVITY; MALE; METABOLOME; METABOLOMICS; MITOCHONDRIAL MEMBRANE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; RETT SYNDROME; SKELETAL MUSCLE; SOCIAL INTERACTION; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; DEFICIENCY; DIET; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HUMAN; LIPID METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PSYCHOLOGY;

MUS;

ANIMALS; BEHAVIOR, ANIMAL; CITRIC ACID CYCLE; DIET; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HUMANS; LIPID METABOLISM; LONGEVITY; MALE; METABOLOME; METHYL-CPG-BINDING PROTEIN 2; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; PHENOTYPE; RETT SYNDROME; TRIGLYCERIDES;

EID: 84907845373     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109527     Document Type: Article

References (82)

1. Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, et al. (2008) MeCP2, a key contributor to neurological disease, activates and represses transcription. Science (New York, NY) 320: 1224-1229.
2. Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY (2002) Insight into Rett syndrome: MeCP2 levels display tissue- And cell-specific differences and correlate with neuronal maturation. Human molecular genetics 11: 115-124.
3. Nomura Y, Segawa M, Hasegawa M (1984) Rett syndrome-clinical studies and pathophysiological consideration. Brain & development 6: 475-486.
4. Nomura Y (2001) Neurophysiology of Rett syndrome. Brain & development 23 Suppl 1: S50-57.
5. Segawa M (2001) Pathophysiology of Rett syndrome from the stand point of clinical characteristics. Brain Dev 23 Suppl 1: S94-98.
6. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, et al. (1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpGbinding protein 2. Nature genetics 23: 185-188.
7. Guy J, Hendrich B, Holmes M, Martin JE, Bird A (2001) A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nature genetics 27: 322-326.
8. Kozinetz CA, Skender ML, MacNaughton N, Almes MJ, Schultz RJ, et al. (1993) Epidemiology of Rett syndrome: A population-based registry. Pediatrics 91: 445-450.
9. Johnston MV (2001) Developmental disorders of activity dependent neuronal plasticity. Indian J Pediatr 68: 423-426.
10. Percy AK (2001) Rett syndrome: clinical correlates of the newly discovered gene. Brain Dev 23 Suppl 1: S202-205.
11. Valenti D, de Bari L, De Filippis B, Henrion-Caude A, Vacca RA (2014) Mitochondrial dysfunction as a central actor in intellectual disability-related diseases: An overview of Down syndrome, autism, Fragile X and Rett syndrome. Neurosci Biobehav Rev.
12. Wallace DC (2005) A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Annual Review of Genetics 39: 359-407.
13. Seo AY, Joseph AM, Dutta D, Hwang JC, Aris JP, et al. (2010) New insights into the role of mitochondria in aging: mitochondrial dynamics and more. Journal of cell science 123: 2533-2542.
14. Coker SB, Melnyk AR (1991) Rett syndrome and mitochondrial enzyme deficiencies. Journal of child neurology 6: 164-166.
15. Dotti MT, Manneschi L, Malandrini A, De Stefano N, Caznerale F, et al. (1993) Mitochondrial dysfunction in Rett syndrome. An ultrastructural and biochemical study. Brain & development 15: 103-106.
16. Eeg-Olofsson O, al-Zuhair AG, Teebi AS, al-Essa MM (1988) Abnormal mitochondria in the Rett syndrome. Brain & development 10: 260-262.
17. Eeg-Olofsson O, al-Zuhair AG, Teebi AS, al-Essa MM (1989) Rett syndrome: genetic clues based on mitochondrial changes in muscle. American Journal of Medical Genetics 32: 142-144.
18. Eeg-Olofsson O, al-Zuhair AG, Teebi AS, Daoud AS, Zaki M, et al. (1990) Rett syndrome: A mitochondrial disease? Journal of child neurology 5: 210-214.
19. Blardi P, de Lalla A, D'Ambrogio T, Vonella G, Ceccatelli L, et al. (2009) Longterm plasma levels of leptin and adiponectin in Rett syndrome. Clinical endocrinology 70: 706-709.
20. Blardi P, de Lalla A, D'Ambrogio T, Zappella M, Cevenini G, et al. (2007) Rett syndrome and plasma leptin levels. The Journal of pediatrics 150: 37-39.
21. Pratte M, Panayotis N, Ghata A, Villard L, Roux JC (2011) Progressive motor and respiratory metabolism deficits in post-weaning Mecp2-null male mice. Behavioural brain research 216: 313-320.
22. Kriaucionis S, Paterson A, Curtis J, Guy J, Macleod N, et al. (2006) Gene expression analysis exposes mitochondrial abnormalities in a mouse model of Rett syndrome. Molecular and cellular biology 26: 5033-5042.
23. Borges K, Sonnewald U (2011) Triheptanoin-A medium chain triglyceride with odd chain fatty acids: A new anaplerotic anticonvulsant treatment? Epilepsy research.
24. Roe CR, Mochel F (2006) Anaplerotic diet therapy in inherited metabolic disease: Therapeutic potential. Journal of inherited metabolic disease 29: 332- 340.
25. Roe CR, Roe DS, Wallace M, Garritson B (2007) Choice of oils for essential fat supplements can enhance production of abnormal metabolites in fat oxidation disorders. Molecular genetics and metabolism 92: 346-350.
26. Brunengraber H, Roe CR (2006) Anaplerotic molecules: current and future. Journal of inherited metabolic disease 29: 327-331.
27. Owen OE, Kalhan SC, Hanson RW (2002) The key role of anaplerosis and cataplerosis for citric acid cycle function. J Biol Chem 277: 30409-30412.
28. Mochel F, DeLonlay P, Touati G, Brunengraber H, Kinman RP, et al. (2005) Pyruvate carboxylase deficiency: clinical and biochemical response to anaplerotic diet therapy. Mol Genet Metab 84: 305-312.
29. Roe CR, Bottiglieri T, Wallace M, Arning E, Martin A (2010) Adult Polyglucosan Body Disease (APBD): Anaplerotic diet therapy (Triheptanoin) and demonstration of defective methylation pathways. Mol Genet Metab 101: 246-252.
30. Roe CR, Sweetman L, Roe DS, David F, Brunengraber H (2002) Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest 110: 259-269.
31. Roe CR, Yang BZ, Brunengraber H, Roe DS, Wallace M, et al. (2008) Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy. Neurology 71: 260-264.
32. Fyffe SL, Neul JL, Samaco RC, Chao HT, Ben-Shachar S, et al. (2008) Deletion of Mecp2 in Sim1-expressing neurons reveals a critical role for MeCP2 in feeding behavior, aggression, and the response to stress. Neuron 59: 947-958.
33. Pitcher MR, Ward CS, Arvide EM, Chapleau CA, Pozzo-Miller L, et al. (2013) Insulinotropic treatments exacerbate metabolic syndrome in mice lacking MeCP2 function. Hum Mol Genet 22: 2626-2633.
34. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI (1992) Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest 90: 1323-1327.
35. Zimmer DB, Magnuson MA (1990) Immunohistochemical localization of phosphoenolpyruvate carboxykinase in adult and developing mouse tissues. J Histochem Cytochem 38: 171-178.
36. Giulivi C, Zhang YF, Omanska-Klusek A, Ross-Inta C, Wong S, et al. (2010) Mitochondrial dysfunction in autism. JAMA: The journal of the American Medical Association 304: 2389-2396.
37. Grosser E, Hirt U, Janc OA, Menzfeld C, Fischer M, et al. (2012) Oxidative burden and mitochondrial dysfunction in a mouse model of Rett syndrome. Neurobiol Dis 48: 102-114.
38. Oliveira G, Diogo L, GrazinaM, Garcia P, Ataide A, et al. (2005) Mitochondrial dysfunction in autism spectrum disorders: A population-based study. Dev Med Child Neurol 47: 185-189.
39. Ruch A, Kurczynski TW, Velasco ME (1989) Mitochondrial alterations in Rett syndrome. Pediatric neurology 5: 320-323.
40. Nomura Y, Segawa M (1992) Motor symptoms of the Rett syndrome: Abnormal muscle tone, posture, locomotion and stereotyped movement. Brain & development 14 Suppl: S21-28.
41. Sirikul B, Gower BA, Hunter GR, Larson-Meyer DE, Newcomer BR (2006) Relationship between insulin sensitivity and in vivo mitochondrial function in skeletal muscle. American journal of physiologyEndocrinology and metabolism 291: E724-728.
42. Kinman RP, Kasumov T, Jobbins KA, Thomas KR, Adams JE, et al. (2006) Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats. Am J Physiol Endocrinol Metab 291: E860-866.
43. Ramsay RR, Zammit VA (2004) Carnitine acyltransferases and their influence on CoA pools in health and disease. Mol Aspects Med 25: 475-493.
44. Hoppel C (2003) The role of carnitine in normal and altered fatty acid metabolism. Am J Kidney Dis 41: S4-12.
45. Nosadini R, Avogaro A, Doria A, Fioretto P, Trevisan R, et al. (1989) Ketone body metabolism: A physiological and clinical overview. Diabetes Metab Rev 5: 299-319.
46. Lopes-Cardozo M, van den Bergh SG (1972) Ketogenesis in isolated rat liver mitochondria. I. Relationships with the citric acid cycle and with the mitochondrial energy state. Biochim Biophys Acta. 1972/01/01 ed. pp. 1-15.
47. Buchovecky CM, Turley SD, Brown HM, Kyle SM, McDonald JG, et al. (2013) A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome. Nat Genet.
48. Katz DM, Berger-Sweeney JE, Eubanks JH, Justice MJ, Neul JL, et al. (2012) Preclinical research in Rett syndrome: setting the foundation for translational success. Dis Model Mech 5: 733-745.
49. Samaco RC, McGraw CM, Ward CS, Sun Y, Neul JL, et al. (2013) Female Mecp2(+/-) mice display robust behavioral deficits on two different genetic backgrounds providing a framework for pre-clinical studies. Hum Mol Genet 22: 96-109.
50. Zappella M, Meloni I, Longo I, Hayek G, Renieri A (2001) Preserved speech variants of the Rett syndrome: molecular and clinical analysis. Am J Med Genet 104: 14-22.
51. Gu L, Zhang GF, Kombu RS, Allen F, Kutz G, et al. (2010) Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats. II. Effects on lipolysis, glucose production, and liver acyl-CoA profile. Am J Physiol Endocrinol Metab 298: E362-371.
52. Deng S, Zhang GF, Kasumov T, Roe CR, Brunengraber H (2009) Interrelations between C4 ketogenesis, C5 ketogenesis, and anaplerosis in the perfused rat liver. J Biol Chem 284: 27799-27807.
53. Ridge KD, Hofmann K, Finn FM (1988) ATP sensitizes the insulin receptor to insulin. Proc Natl Acad Sci U S A 85: 9489-9493.
54. O'Brien RM, Granner DK (1990) PEPCK gene as model of inhibitory effects of insulin on gene transcription. Diabetes Care 13: 327-339.
55. Yang J, Kalhan SC, Hanson RW (2009) What is the metabolic role of phosphoenolpyruvate carboxykinase? J Biol Chem 284: 27025-27029.
56. Burgess SC, He T, Yan Z, Lindner J, Sherry AD, et al. (2007) Cytosolic phosphoenolpyruvate carboxykinase does not solely control the rate of hepatic gluconeogenesis in the intact mouse liver. Cell Metab 5: 313-320.
57. Lemasters JJ, Nieminen AL, Qian T, Trost LC, Herman B (1997) The mitochondrial permeability transition in toxic, hypoxic and reperfusion injury. Mol Cell Biochem 174: 159-165.
58. Fiskum G, Starkov A, Polster BM, Chinopoulos C (2003) Mitochondrial mechanisms of neural cell death and neuroprotective interventions in Parkinson's disease. Ann N Y Acad Sci 991: 111-119.
59. Weiss JN, Korge P, Honda HM, Ping P (2003) Role of the mitochondrial permeability transition in myocardial disease. Circ Res 93: 292-301.
60. Halestrap AP (2006) Calcium, mitochondria and reperfusion injury: A pore way to die. Biochem Soc Trans 34: 232-237.
61. Yamada T, Zhang SJ, Westerblad H, Katz A (2010) {beta}-Hydroxybutyrate inhibits insulin-mediated glucose transport in mouse oxidative muscle. Am J Physiol Endocrinol Metab 299: E364-373.
62. Haas RH, Rice MA, Trauner DA, Merritt TA (1986) Therapeutic effects of a ketogenic diet in Rett syndrome. Am J Med Genet Suppl 1: 225-246.
63. Liebhaber GM, Riemann E, Baumeister FA (2003) Ketogenic diet in Rett syndrome. J Child Neurol 18: 74-75.
64. Willis S, Stoll J, Sweetman L, Borges K (2010) Anticonvulsant effects of a triheptanoin diet in two mouse chronic seizure models. Neurobiol Dis 40: 565- 572.
65. Kim TH, Borges K, Petrou S, Reid CA (2013) Triheptanoin reduces seizure susceptibility in a syndrome-specific mouse model of generalized epilepsy. Epilepsy Res 103: 101-105.
66. Moretti P, Levenson JM, Battaglia F, Atkinson R, Teague R, et al. (2006) Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome. J Neurosci 26: 319-327.
67. Belichenko PV, Wright EE, Belichenko NP, Masliah E, Li HH, et al. (2009) Widespread changes in dendritic and axonal morphology in Mecp2-mutant mouse models of Rett syndrome: evidence for disruption of neuronal networks. J Comp Neurol 514: 240-258.
68. Landi S, Putignano E, Boggio EM, Giustetto M, Pizzorusso T, et al. (2011) The short-time structural plasticity of dendritic spines is altered in a model of Rett syndrome. Sci Rep 1: 45.
69. Gemelli T, Berton O, Nelson ED, Perrotti LI, Jaenisch R, et al. (2006) Postnatal loss of methyl-CpG binding protein 2 in the forebrain is sufficient to mediate behavioral aspects of Rett syndrome in mice. Biol Psychiatry 59: 468-476.
70. Dhar SS, Liang HL, Wong-Riley MT (2009) Transcriptional coupling of synaptic transmission and energy metabolism: role of nuclear respiratory factor 1 in co-regulating neuronal nitric oxide synthase and cytochrome c oxidase genes in neurons. Biochim Biophys Acta 1793: 1604-1613.
71. Kaufmann WE, Johnston MV, Blue ME (2005) MeCP2 expression and function during brain development: implications for Rett syndrome's pathogenesis and clinical evolution. Brain Dev 27 Suppl 1: S77-S87.
72. Cornford ME, Philippart M, Jacobs B, Scheibel AB, Vinters HV (1994) Neuropathology of Rett syndrome: case report with neuronal and mitochondrial abnormalities in the brain. J Child Neurol 9: 424-431.
73. Lioy DT, Garg SK, Monaghan CE, Raber J, Foust KD, et al. (2011) A role for glia in the progression of Rett's syndrome. Nature 475: 497-500.
74. De Filippis B, Fabbri A, Simone D, Canese R, Ricceri L, et al. (2012) Modulation of RhoGTPases improves the behavioral phenotype and reverses astrocytic deficits in a mouse model of Rett syndrome. Neuropsychopharmacology 37: 1152-1163.
75. Heilstedt HA, Shahbazian MD, Lee B (2002) Infantile hypotonia as a presentation of Rett syndrome. American Journal of Medical Genetics 111: 238-242.
76. De Felice C, Maffei S, Signorini C, Leoncini S, Lunghetti S, et al. (2012) Subclinical myocardial dysfunction in Rett syndrome. Eur Heart J Cardiovasc Imaging 13: 339-345.
77. Degano AL, Park MJ, Penati J, Li Q, Ronnett GV (2014) MeCP2 is required for activity-dependent refinement of olfactory circuits. Mol Cell Neurosci 59: 63-75.
78. Degano AL, Pasterkamp RJ, Ronnett GV (2009) MeCP2 deficiency disrupts axonal guidance, fasciculation, and targeting by altering Semaphorin 3F function. Molecular and cellular neurosciences 42: 243-254.
79. Chen RZ, Akbarian S, Tudor M, Jaenisch R (2001) Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 27: 327-331.
80. Moretti P, Bouwknecht JA, Teague R, Paylor R, Zoghbi HY (2005) Abnormalities of social interactions and home-cage behavior in a mouse model of Rett syndrome. Human molecular genetics 14: 205-220.
81. Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, et al. (2011) Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A 108: 3270-3275.
82. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E (2009) Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 81: 6656-6667.